Neoprobe’s Phase III Lymphoseek Study Achieves Positive Results

Neoprobe Corporation, a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced that a multicenter Phase 3 study of Lymphoseek has reached the accrual of 203 lymph nodes, the study’s primary accrual objective.
iStockAnalyst.com